Extract

This randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety and efficacy of RO4917523 as adjunctive therapy in patients with major depressive disorder and an inadequate response to ongoing antidepressant therapy. Anticipated time on study treatment is 6 weeks with a 3-week follow-up.

Inclusion criteria

• Major Depressive Disorder

Country

• Chile
• Germany
• Japan
• Mexico
• Poland
• Romania
• Russian Federation
• Taiwan, Province of China
• United States

Links

• ictrp
• nct